DFTX Definium Therapeutics, Inc.
Company Analysis
Latest News
🔴 Definium Therapeutics is trading 4% down today amid renewed U.S.-Iran tensions
Definium Therapeutics is trading at $39.34, down 4.00%, amid broad risk-off pressure linked to renewed U.S.-Iran tensions, higher oil prices, and increased...
🔴 Definium Therapeutics falls 4.1% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🟢 Definium Therapeutics rises 4.2% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
🔴 Definium Therapeutics is trading 5% down today amid elevated Treasury yields
Definium Therapeutics is trading 5.06% down now at $42.64 amid a mixed-to-lower market, with the Nasdaq Composite down 0.57% and risk assets pressured by...
Definium Therapeutics Rated Buy at BofA, Citing Multi-Billion LSD Drug Potential
Bank of America initiated coverage on Definium Therapeutics with a Buy rating and a $75.00 price target. This valuation suggests a potential upside of over 65%...
🔴 Definium Therapeutics is trading 4.2% down today — no fresh company-specific negative catalyst identified
Definium Therapeutics is trading 4.2% down at $42.05, with no fresh company-specific negative catalyst identified on August 14, 2026. - The latest major...
🟢 Definium Therapeutics is trading 4.03% up today after positive Phase 3 Voyage results
Definium Therapeutics is trading 4.03% up now at $44.52 after positive Phase 3 Voyage results announced August 12, 2026. - The DT120 ODT study met its primary...
🟢 Definium Therapeutics is trading 8% up today after positive Phase 3 Voyage anxiety results
Definium Therapeutics is trading at $44.22 (+8.09%) after positive Phase 3 Voyage results for DT120 ODT in generalized anxiety disorder. - The study met its...
DFTX Reports Positive Phase 3 Results for DT120 in Generalized Anxiety Disorder Study
Definium Therapeutics announced positive topline results from its Phase 3 Voyage study evaluating DT120 ODT for the treatment of generalized anxiety disorder...
Definium's Anxiety Drug Aces Its Final Trial — But Can a Single Win Justify a $50 Stock Price?
Shares of Definium Therapeutics surged 22.2% to $50.00 after the company announced its Voyage Phase 3 trial for generalized anxiety disorder hit its primary...
🟢 Definium Therapeutics is trading 22.22% up in pre-market after Voyage Phase 3 met primary endpoint
Definium Therapeutics is trading at $50.00 (+22.22%) after Voyage Phase 3 met its primary endpoint in generalized anxiety disorder. - DT120 ODT delivered a...
🔴 Definium Therapeutics is trading 4.36% down today with Voyage results pending
Definium Therapeutics is trading 4.36% down at $43.18, with no clearly reported company-specific announcement explaining the August 11, 2026 decline. - The...
🔴 Definium Therapeutics is trading 4.03% down today; no clear company-specific catalyst identified
Definium Therapeutics is trading 4.03% down at $44.28, with no clear company-specific announcement identified to explain the August 10, 2026 decline. -...
🟢 Definium Therapeutics is trading 4.2% up today amid broader biotech strength and positive sector sentiment
Definium Therapeutics is trading at $44.09 (+4.18%) amid a firmer biotech tape and positive sector-wide earnings sentiment, despite no company-specific news...
🔴 Definium Therapeutics is trading 4.2% down today on apparent profit-taking
Definium Therapeutics is trading 4.2% down at $41.71 today, with the intraday weakness appearing to be driven by normal volatility and profit-taking following...
Definium Therapeutics upgraded to strong-buy, backed by FDA breakthrough drug
Wells Fargo & Company upgraded Definium Therapeutics, Inc. (NASDAQ: DFTX) to a strong-buy rating on Tuesday. The biotechnology firm develops therapeutics for...
Definium Therapeutics, Inc. Q2 2026 Earnings Preview: What Analysts Expect on July 30, 2026
Definium Therapeutics is projected to report zero revenue and a consensus EPS of -$0.56 for the second quarter of 2026, with the current stock price of $43.17...
🔴 Definium Therapeutics falls 4.6% — Biotech Stocks Decline on Broad Market Weakness
With Biotech (XBI) down 2.2%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
Definium Therapeutics Rated Overweight, Wells Fargo Cites Mood Disorder Drug Potential
Wells Fargo initiated coverage of Definium Therapeutics (DFTX) on July 27, 2026. Analyst Benjamin Burnett assigned the biotechnology firm an Overweight...
🟢 Definium Therapeutics is trading 4.3% up today amid a broader biotech and psychedelic sector rally
Definium Therapeutics is trading 4.3% up today at $45.03, continuing a strong multi-week run ahead of its next earnings report. • The move is driven by...